psoriasis – Medxy AI

Antibiotic Exposure Linked to Shorter Biologic Survival in Psoriasis: A Large French Cohort Suggests a Dose–Response Relationship

By MedXY 11/17/2025

A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting antibiotic-associated dysbiosis may reduce biologic persistence.

Dermatology news

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs

By MedXY 11/10/2025

Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and fewer adverse events than deucravacitinib through 24 weeks.

Dermatology Family Medicine & Nutrition Specialties

Mediterranean Diet as Adjunct Therapy in Psoriasis: Insights from the MEDIPSO Randomized Clinical Trial

By MedXY 09/28/2025

A 16-week Mediterranean diet intervention significantly reduced psoriasis severity and improved metabolic markers in patients with mild to moderate disease, suggesting diet’s role as adjunctive therapy in psoriasis management.

Allergy & Immunology Dermatology Specialties

Icotrokinra: A Promising Oral IL-23 Inhibitor Outperforms JAK Inhibitor in Psoriasis Phase 3 Trials

By MedXY 09/25/2025

In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psoriasis therapies.